123391_241211_Embla_Medical_Initiation_Stepping_into_the_Future.pdf

Embla Medical

Embla Medical, der tidligere var kendt under navnet Össur, har fået indledt sin dækning med anbefalingen "køb" af finanshuset Intron Health.

Kursmålet for det islandske proteseselskab sættes i samme ombæring til 56 kr., skriver Bloomberg News.

Aktien steg mandag med 2,5 pct. til 36,90 kr., efter at Nordea løftede sit kursmål for aktien til 43,20 kr. fra 41 kr.

.\˙ MarketWire

Target price DKK 44.00

"Low penetration and attractive competitive situation With the penetration rate of high-function orthoses being well below 5% in developed markets, we see ample headroom for growth. The key competitor is Ottobock while other companies mainly target low-function products, creating an attractive duopolistic situation, in our view.

Plus the call highlighted that Fior & Gentz provides highly personalised treatment, and thanks to its unique configurator the company offers ~500,000 potential configurations. This, combined with the sales synergies, makes us believe that Fior & Gentz

Buy: Valuation still not demanding, in our view, despite solid run While the share is up 35% YTD, this on a par with EPS growth. Hence, it still trades at the low end of its historical 10-year multiple range"